The American College of Rheumatology and the Arthritis Foundation have released updated recommendations for the screening, monitoring, and treatment of juvenile idiopathic arthritis with associated uveitis.
The American College of Rheumatology and Arthritis Foundation have released updated guidelines for management of non-systemic polyarthritis, sacroiliitis, and enthesitis in patients with juvenile idiopathic arthritis.
Patients with JIA who received tocilizumab therapy experienced transient neutropenia that was not associated with an increased number of infections.
Although there was high agreement and similar classification of change among the questionnaires, these may not be completely interchangeable.
Data show that more than half of patients with juvenile idiopathic arthritis were no longer on methotrexate therapy.
An algorithm that can classify patients with juvenile idiopathic arthritis (JIA) into seven distinct groups based on patterns of swollen or painful joints in the body can help predict disease course.
Long-term follow-up data show that many adult patients with JIA have active disease with low remission rates.
Patients with juvenile idiopathic arthritis demonstrated evidence of dysbiosis and reduced diversity in the gut microbiome.
Discontinuing TNFi therapy before 20 weeks gestation was feasible in women with RA and JIA who enter pregnancy with well-controlled disease.
National and international pharmacovigilance registry data pertaining to the use of biologic agents in patients with juvenile idiopathic arthritis have been combined.
